Vir Biotechnology (VIR) EBITDA Margin Growth (3y) (2021 - 2026)

Vir Biotechnology (VIR) EBITDA Margin Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 Vir Biotechnology 1.56 Bn 1.56 Bn 238.95 Mn 569,801.00

Historic Data

Download Data
DateValue
Jun 30, 2026 569,801.00
Mar 31, 2026 -45.59 Mn
Dec 31, 2025 22,980.00
Sep 30, 2025 -7.23 Mn
Jun 30, 2025 -919,995.00
Mar 31, 2025 -468,473.00
Dec 31, 2024 -101,709.00
Sep 30, 2024 -966,713.00
Jun 30, 2024 -519,495.00
Mar 31, 2024 787,309.00
Dec 31, 2023 542,356.00
Sep 30, 2023 -253,152.00
Jun 30, 2023 -560,017.00
Mar 31, 2023 102,988.00
Dec 31, 2022 620,142.00
Sep 30, 2022 345,048.00
Jun 30, 2022 119,305.00
Mar 31, 2022 92,274.00
Dec 31, 2021 92,755.00
Sep 30, 2021 113,898.00